Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy

Research output: Contribution to journalReview article

Abstract

Introduction: Cardiotoxicity is a common complication that may compromise the clinical effectiveness of anticancer therapy. The current standard for monitoring cardiac function detects cardiotoxicity only when a functional impairment has already occurred, not allowing for any early preventive strategy. Areas covered: A novel approach, based on the use of biomarkers has recently emerged, resulting in a very effective tool for early, real-time identification, and monitoring of cardiotoxicity. In particular, cardiac troponin elevation during chemotherapy allows to identify patients more prone to develop myocardial dysfunction and cardiac events. In these patients, use of angiotensin-converting enzyme inhibitors, such as enalapril, has shown to be effective in improving clinical outcomes, giving the chance for cardioprotective strategies in a selected population. The authors reviewed the currently available data about the role of biomarkers in this setting. Expert commentary: Early identification of patients at high risk of cardiotoxicity by cardiac biomarkers–in particular troponin–provides a rationale for targeted preventive strategies against cancer therapy-induced left ventricular dysfunction and its associated clinical complications, with the advantage of limiting prophylactic therapy only to a restricted number of patients. Although the major international oncologic societies encourage this approach, some limitations to a routinely use of biomarkers still exist.

Original languageEnglish
Pages (from-to)245-256
Number of pages12
JournalExpert Review of Molecular Diagnostics
Volume17
Issue number3
DOIs
Publication statusPublished - Mar 4 2017

Fingerprint

Biomarkers
Neoplasms
Enalapril
Troponin
Left Ventricular Dysfunction
Therapeutics
Angiotensin-Converting Enzyme Inhibitors
Drug Therapy
Cardiotoxicity
Population

Keywords

  • ACE-inhibitors
  • biomarkers
  • Cardiotoxicity
  • chemotherapy
  • natriuretic peptides
  • prevention
  • troponin

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

@article{a67445f8ae244e309ddd65316408ee10,
title = "Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy",
abstract = "Introduction: Cardiotoxicity is a common complication that may compromise the clinical effectiveness of anticancer therapy. The current standard for monitoring cardiac function detects cardiotoxicity only when a functional impairment has already occurred, not allowing for any early preventive strategy. Areas covered: A novel approach, based on the use of biomarkers has recently emerged, resulting in a very effective tool for early, real-time identification, and monitoring of cardiotoxicity. In particular, cardiac troponin elevation during chemotherapy allows to identify patients more prone to develop myocardial dysfunction and cardiac events. In these patients, use of angiotensin-converting enzyme inhibitors, such as enalapril, has shown to be effective in improving clinical outcomes, giving the chance for cardioprotective strategies in a selected population. The authors reviewed the currently available data about the role of biomarkers in this setting. Expert commentary: Early identification of patients at high risk of cardiotoxicity by cardiac biomarkers–in particular troponin–provides a rationale for targeted preventive strategies against cancer therapy-induced left ventricular dysfunction and its associated clinical complications, with the advantage of limiting prophylactic therapy only to a restricted number of patients. Although the major international oncologic societies encourage this approach, some limitations to a routinely use of biomarkers still exist.",
keywords = "ACE-inhibitors, biomarkers, Cardiotoxicity, chemotherapy, natriuretic peptides, prevention, troponin",
author = "Daniela Cardinale and Gina Biasillo and Michela Salvatici and Sandri, {Maria Teresa} and Cipolla, {Carlo Maria}",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/14737159.2017.1283219",
language = "English",
volume = "17",
pages = "245--256",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy

AU - Cardinale, Daniela

AU - Biasillo, Gina

AU - Salvatici, Michela

AU - Sandri, Maria Teresa

AU - Cipolla, Carlo Maria

PY - 2017/3/4

Y1 - 2017/3/4

N2 - Introduction: Cardiotoxicity is a common complication that may compromise the clinical effectiveness of anticancer therapy. The current standard for monitoring cardiac function detects cardiotoxicity only when a functional impairment has already occurred, not allowing for any early preventive strategy. Areas covered: A novel approach, based on the use of biomarkers has recently emerged, resulting in a very effective tool for early, real-time identification, and monitoring of cardiotoxicity. In particular, cardiac troponin elevation during chemotherapy allows to identify patients more prone to develop myocardial dysfunction and cardiac events. In these patients, use of angiotensin-converting enzyme inhibitors, such as enalapril, has shown to be effective in improving clinical outcomes, giving the chance for cardioprotective strategies in a selected population. The authors reviewed the currently available data about the role of biomarkers in this setting. Expert commentary: Early identification of patients at high risk of cardiotoxicity by cardiac biomarkers–in particular troponin–provides a rationale for targeted preventive strategies against cancer therapy-induced left ventricular dysfunction and its associated clinical complications, with the advantage of limiting prophylactic therapy only to a restricted number of patients. Although the major international oncologic societies encourage this approach, some limitations to a routinely use of biomarkers still exist.

AB - Introduction: Cardiotoxicity is a common complication that may compromise the clinical effectiveness of anticancer therapy. The current standard for monitoring cardiac function detects cardiotoxicity only when a functional impairment has already occurred, not allowing for any early preventive strategy. Areas covered: A novel approach, based on the use of biomarkers has recently emerged, resulting in a very effective tool for early, real-time identification, and monitoring of cardiotoxicity. In particular, cardiac troponin elevation during chemotherapy allows to identify patients more prone to develop myocardial dysfunction and cardiac events. In these patients, use of angiotensin-converting enzyme inhibitors, such as enalapril, has shown to be effective in improving clinical outcomes, giving the chance for cardioprotective strategies in a selected population. The authors reviewed the currently available data about the role of biomarkers in this setting. Expert commentary: Early identification of patients at high risk of cardiotoxicity by cardiac biomarkers–in particular troponin–provides a rationale for targeted preventive strategies against cancer therapy-induced left ventricular dysfunction and its associated clinical complications, with the advantage of limiting prophylactic therapy only to a restricted number of patients. Although the major international oncologic societies encourage this approach, some limitations to a routinely use of biomarkers still exist.

KW - ACE-inhibitors

KW - biomarkers

KW - Cardiotoxicity

KW - chemotherapy

KW - natriuretic peptides

KW - prevention

KW - troponin

UR - http://www.scopus.com/inward/record.url?scp=85013243618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013243618&partnerID=8YFLogxK

U2 - 10.1080/14737159.2017.1283219

DO - 10.1080/14737159.2017.1283219

M3 - Review article

C2 - 28092472

AN - SCOPUS:85013243618

VL - 17

SP - 245

EP - 256

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 3

ER -